2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cyngn reported second-quarter 2026 results with revenue of $144,459, up from $33,726 a year earlier, while its net loss widened to $6.4 million from $5.4 million as total costs rose 25%. The company said commercial execution was delayed relative to its expectations, and it has reduced management layers and changed sales leadership. Cash and short-term investments totaled $39.7 million at June 30, 2026, and the company reported no debt.
Q2 2026 revenue was $144,459, compared with $33,726 in Q2 2025.
Q2 2026 net loss was $(6.4) million, or $(0.45) per share, on about 14.1 million weighted-average shares, versus $(5.4) million, or $(2.70) per share, on about 2.0 million shares in Q2 2025.
Total costs and expenses rose $1.4 million, or 25%, to $6.9 million, mainly from a $1.2 million increase in research and development.
Cash and short-term investments were $39.7 million at June 30, 2026, versus $34.7 million at December 31, 2025.
BioStem Technologies reported second quarter 2026 results on August 12, 2026, with net revenue of $7.9 million, up 29% from $6.1 million in the first quarter but down from $11.0 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $26 million to $29 million, but posted a GAAP net loss of $9.0 million, or $0.52 per share, and cash and cash equivalents fell to $7.0 million at June 30, 2026.
Net revenue of $7.9 million, up 29% from $6.1 million in Q1 2026 and down from $11.0 million in Q2 2025
GAAP net loss of $9.0 million, or $0.52 per share, versus net income of $10,613 in Q2 2025; gross margin 61% versus 94% a year earlier
Full-year 2026 revenue guidance raised to $26 million to $29 million from $25 million to $29 million
Cash and cash equivalents of $7.0 million at June 30, 2026, compared with $13.7 million at the end of Q1 2026
GMR Solutions reported second-quarter 2026 net revenue of $1,490.3 million, up 3.3%, but swung to a net loss of $28.3 million from net income of $80.8 million a year earlier. Adjusted EBITDA fell 11.8% to $284.5 million, and the company reaffirmed its full-year 2026 guidance, which means shareholders should weigh the revenue growth against lower profit.
Q2 2026 net revenue was $1,490.3 million, up 3.3% from $1,442.0 million in Q2 2025.
Q2 2026 net loss was $28.3 million, compared with net income of $80.8 million in Q2 2025; adjusted EBITDA was $284.5 million, down 11.8%.
Full-year 2026 guidance was reaffirmed: net revenue of $5,890 million to $6,180 million and adjusted EBITDA of $1,135 million to $1,195 million.
The CFO said the prior-year period benefited from a $74.3 million year-over-year difference in revenue estimate changes tied to No Surprises Act collections.
M-tron Industries (Mtron) reported second-quarter 2026 results, with revenue up 13.8% to $15.1 million and net income up 19.9% to $1.9 million. Diluted earnings per share fell to $0.43 from $0.53, which the company attributes to more weighted shares outstanding after a rights offering completed in April 2026. Shareholders get higher sales and profit in dollar terms, but per-share earnings were diluted, and management will discuss the results on a call on August 13, 2026.
Revenue of $15.1 million for the quarter, up 13.8% from $13.3 million a year earlier
Net income of $1.9 million, up 19.9%; diluted EPS of $0.43 versus $0.53, down 18.9%
Diluted EPS decline attributed to higher weighted shares outstanding from the rights offering completed in April 2026
Backlog of $84.0 million as of June 30, 2026, up 37.2% from $61.2 million a year earlier; conference call August 13, 2026 at 10:30 a.m. ET
Dolphin Entertainment reported second-quarter 2026 revenue of $14.4 million, up 2.5% from a year earlier, and first-half revenue of $27.2 million, up 3.8%. Net loss rose to $1.6 million from $1.4 million, and adjusted EBITDA fell to about $243,000 from about $628,000, as retention bonuses and litigation-related legal costs weighed on results.
Q2 2026 revenue was $14.4 million versus $14.1 million in Q2 2025; H1 2026 revenue was $27.2 million versus $26.3 million.
Q2 2026 operating loss was $1.0 million versus $0.1 million in Q2 2025; net loss was $1.6 million, or $(0.13) per share, unchanged from the prior-year loss per share.
Retention bonuses of $360,000 and litigation-related costs of about $0.4 million affected the quarter; the company says the bonuses are not expected to recur.
Cash and cash equivalents were $7.7 million at June 30, 2026, down from $8.8 million at December 31, 2025.
Park Dental Partners reported second-quarter 2026 revenue up 5.1% to $66.2 million, but net income fell 47.5% to $1.3 million, or $0.22 per diluted share, from $2.6 million, or $1.45, a year earlier. The company also issued full-year 2026 outlook of $256.0 million to $260.0 million in revenue and $21.0 million to $23.0 million in Adjusted EBITDA, excluding the pending Village Family DSO acquisition.
Q2 2026 revenue rose 5.1% to $66.2 million; Adjusted EBITDA fell 1.7% to $7.4 million.
Q2 2026 diluted EPS was $0.22 versus $1.45 in Q2 2025; adjusted diluted EPS was $0.66 versus $1.88.
2026 outlook: revenue $256.0 million to $260.0 million; Adjusted EBITDA $21.0 million to $23.0 million, compared with 2025 actual revenue of $244.5 million and Adjusted EBITDA of $22.0 million.
Entered a definitive agreement to acquire Village Family DSO, expected to close later this year; the outlook does not include it.
Kimball Electronics reported fourth-quarter fiscal 2026 net sales of $371.6 million, down 2% from a year earlier but up 5% from the prior quarter. Adjusted diluted EPS was a loss of $0.01, compared with $0.34 a year earlier, while GAAP diluted EPS rose to $0.35 from $0.26, helped by a $15.0 million gain on disposal. The company guided fiscal 2027 net sales of $1,535 million to $1,560 million, which includes about $60 million from the Helvoet acquisition.
Q4 net sales $371.6 million vs. $380.5 million a year earlier; adjusted operating income $18.1 million vs. $19.6 million
Q4 GAAP diluted EPS $0.35 vs. $0.26; adjusted diluted EPS $(0.01) vs. $0.34
Fiscal 2026 net sales $1,431.4 million, down 4% from $1,486.7 million; adjusted diluted EPS $1.09 vs. $1.12
Fiscal 2027 guidance: net sales $1,535 million to $1,560 million (7% to 9% growth) and adjusted operating income of 4.4% to 4.7% of net sales
Stem, Inc. reported results for the quarter ended June 30, 2026, with revenue down 12% year over year to $33.7 million and a net loss of $14.4 million, compared with net income of $202.5 million a year earlier that included a one-time gain on debt extinguishment. Adjusted EBITDA rose 63% to $6.2 million, and the company reaffirmed its full-year 2026 guidance across all metrics.
Revenue was $33.7 million, down from $38.4 million in Q2 2025, due to significantly reduced battery hardware resales and lower managed services revenue.
Software, services, and edge hardware revenue rose 1% to $33.4 million, with PowerTrack software revenue up 11% year over year.
Net loss was $14.4 million versus net income of $202.5 million in Q2 2025; the prior-year quarter included a one-time gain on extinguishment of debt.
Full-year 2026 guidance was reaffirmed, including revenue of $140 million to $190 million and adjusted EBITDA of $10 million to $15 million.
Solidion Technology reported second-quarter 2026 results in a press release furnished under Item 2.02. Net sales were $124,914, up from $4,000 a year earlier, mainly from government grant revenue, while the net loss widened to $2.9 million from a restated $2.1 million. The company said that after a $35 million private placement, substantial doubt about its ability to continue as a going concern has been alleviated.
Net sales of $124,914 for the quarter ended June 30, 2026, versus $4,000 a year earlier, mainly from government grant revenue.
Net loss of $2.9 million, or $0.35 per basic share, versus a restated $2,113,859 loss a year earlier; includes a $917,780 loss from change in fair value of derivative liabilities.
Cash and cash equivalents of $27.7 million at June 30, 2026, compared with $0.2 million at December 31, 2025.
A $35 million private placement closed June 9, 2026; the company said the going concern doubt was alleviated after it closed.
Fossil Group reported fiscal second-quarter 2026 net sales of $209.7 million, down 4.9% from $220.4 million a year earlier, and a net loss of $10.6 million, or $0.18 per diluted share, versus a $2.3 million loss, or $0.04 per share, in the prior-year quarter. The company also raised its full-year 2026 outlook, now calling for worldwide net sales to decline 3% to 5% and an adjusted operating margin of 4% to 6%, with positive free cash flow.
Gross margin rose 490 basis points to 62.4%, but operating expenses rose 7.9% to $127.6 million.
Operating income was $3.2 million, compared with $8.5 million in the second quarter of 2025; constant currency adjusted operating income was $8.6 million, compared with $4.3 million in the prior-year quarter.
Cash and cash equivalents were $79.0 million at July 4, 2026, and total debt was $203.0 million.
Full-year guidance: worldwide net sales down 3% to 5%, with a return to growth expected in the fourth quarter.
Marchex reported second-quarter 2026 revenue of $11.0 million, down from $11.7 million a year earlier, and a net loss of $0.4 million, or $(0.01) per diluted share, compared with net income of $0.1 million a year earlier. Adjusted EBITDA rose to $0.7 million from $0.6 million, but the Archenia acquisition, which closed July 1, 2026, is not included in these reported results, and the company gave a third-quarter pro forma combined revenue outlook of $16.0 million to $16.5 million.
Q2 2026 revenue was $11.0 million, compared with $11.7 million in Q2 2025.
Q2 2026 net loss was $0.4 million, or $(0.01) per diluted share, versus net income of $0.1 million, or $0.00 per share, a year earlier.
Adjusted EBITDA was $0.7 million, including $1.0 million of reorganization and acquisition-related costs; adjusted non-GAAP income per share was $0.00 versus $0.02.
Third-quarter 2026 pro forma combined outlook: revenue of $16.0 million to $16.5 million and adjusted EBITDA, net of reorganization and acquisition costs, of $2.3 million to $2.5 million.
Infleqtion reported second-quarter 2026 revenue of $12.6 million, up 116% year over year, and raised its full-year 2026 revenue outlook to approximately $43 million. The net loss widened to $25.5 million from $8.8 million a year earlier, and the company ended the quarter with $582 million in cash, cash equivalents, restricted cash and available-for-sale securities and no debt.
Q2 2026 revenue was $12.6 million, up 116% year over year; the company said growth was 100% organic and entirely from quantum
GAAP operating loss was $30.6 million, compared with $10.1 million in Q2 2025; non-GAAP operating loss was $17.0 million, compared with $7.3 million
2026 revenue outlook was raised to approximately $43 million, and the 30 logical qubit target was reiterated
Results included a $27.4 million temporary working-capital benefit from payroll taxes not yet remitted; the company expects to remit it in Q3
BitGo reported second-quarter 2026 revenue of $4.3 billion, up 79.6% from a year earlier, but swung to a net loss of $19.0 million from a net income of $38.3 million in Q2 2025. The same day, CFO Edward Reginelli said he will resign effective September 15, 2026, and the company has started a search for his successor.
Total revenue of $4.3 billion in Q2 2026, up 79.6% year-over-year and 14.7% sequentially, driven mainly by Digital Asset Sales
Net loss of $19.0 million, or $(0.16) per share, compared with net income of $38.3 million in Q2 2025, mainly due to an $18.8 million unrealized loss on digital assets
Adjusted EBITDA loss of $4.2 million; the company authorized a share repurchase program of up to $50 million
CFO Edward Reginelli to resign effective September 15, 2026, then serve in an advisory role during the transition
AEVEX Corp. agreed on August 12, 2026 to acquire Maritime Applied Physics Corporation's parent-held BlackSea Technologies business in a deal with a $600 million enterprise value, plus up to $50 million in contingent consideration. The Company will pay mostly in cash and about 12.7 million newly issued Class A shares, which adds dilution for existing stockholders, and it expects BlackSea to generate $150 million in fiscal 2026 revenue.
Enterprise value of $600 million; up to $650 million including $50 million in performance-based contingent consideration tied to revenue and gross profit targets through December 31, 2027
Closing consideration includes about 12,727,273 Class A shares valued at $350 million ($27.50 per share) and cash, funded from cash on hand and existing credit facilities
Closing is expected in September 2026, subject to HSR antitrust clearance and NYSE listing approval; no stockholder vote is required
Company says BlackSea is expected to generate $150 million in FY 2026 revenue; issued shares are capped at 19.99% of outstanding stock and carry a 180-day transfer restriction
Armata Pharmaceuticals reported second-quarter 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. Operating loss widened to $10.3 million from $6.8 million a year earlier, and the company's cash and equivalents were $24.0 million at June 30, 2026, so the profit does not reflect improved operations.
Q2 2026 grant and award revenue was $2.5 million, up from $2.2 million in Q2 2025.
Q2 2026 research and development expenses rose to $7.6 million and general and administrative expenses to $5.2 million, mainly from higher non-cash stock-based compensation.
Q2 2026 diluted loss per share was $0.27, compared with $0.45 in Q2 2025; basic earnings per share were $2.02.
Six-month net loss widened to $41.2 million from $22.8 million; cash and equivalents were $24.0 million at June 30, 2026.
MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from a year earlier, while its net loss narrowed to $8.9 million from $12.4 million. The company reiterated full-year 2026 revenue guidance of $30 million to $32 million, so shareholders get a smaller loss alongside a shrinking top line.
Total revenue $7.3 million vs. $8.5 million in Q2 2025, down 15%; core revenue down 21% to $6.5 million
Net loss $8.9 million vs. $12.4 million a year earlier; operating expenses $15.8 million vs. $21.2 million
Full-year 2026 revenue guidance of $30 million to $32 million reiterated; year-end cash expected to be at least $130.5 million
Repurchased about $5.5 million of common stock to date under a $10 million buyback; cash and investments $141.9 million at June 30, 2026
Lulus reported second quarter 2026 results for the period ended June 28, 2026, with net revenue down 17% year over year to $67.8 million. Net loss narrowed to $1.5 million from $3.0 million, and gross margin rose 330 basis points to 48.6%, but the company said revenue trends remain below historical levels. The company reaffirmed its fiscal 2026 outlook, including positive Adjusted EBITDA and capital expenditures of $2.0 million to $2.5 million.
Net revenue fell 17% to $67.8 million, driven by a 17% decrease in Total Orders Placed and higher return rates.
Net loss was $1.5 million, or $(0.52) per share, compared with a net loss of $3.0 million, or $(1.08) per share, a year earlier.
Gross margin increased to 48.6% from 45.3%, and inventory fell 23% to $28.6 million.
Lulus reaffirmed its fiscal 2026 outlook for positive Adjusted EBITDA and net revenue growth trend improvement.
Virgin Galactic reported a second-quarter 2026 net loss of $56 million, down from $67 million a year earlier, helped by an $8.6 million gain on extinguishment of debt. Revenue fell to $0.1 million from $0.4 million, and the company said its first commercial spaceflight has moved to February 2027 from the fourth quarter of 2026 to complete systems installations.
Net loss of $56 million versus $67 million in Q2 2025; revenue of $0.1 million versus $0.4 million
First commercial spaceflight moved to February 2027 from the fourth quarter of 2026
Free cash flow guidance: $(95) million to $(100) million in Q3 2026 and $(80) million to $(90) million in Q4 2026
Cash, cash equivalents and marketable securities of $286 million as of June 30, 2026
Connect Biopharma reported results for the three and six months ended June 30, 2026. Revenue rose to $2.8 million for the quarter, mainly from a regulatory milestone under its Simcere license, but the net loss widened to $17.3 million, or $0.27 per share, from $12.9 million, or $0.23 per share, a year earlier, as research and development expense nearly doubled. The company said its $31.5 million in cash, cash equivalents and short-term investments should fund operations for at least one year from the release date, and it expects topline data from its two Phase 2 Seabreeze STAT studies in September 2026.
Q2 2026 license and collaboration revenue was $2.8 million, versus $48,000 in Q2 2025, primarily from a regulatory-based milestone net of development cost sharing.
Q2 2026 research and development expense was $16.3 million, up from $8.8 million, mainly due to rademikibart development costs for the Seabreeze STAT studies.
Q2 2026 net loss was $17.3 million, or $0.27 per share, compared with $12.9 million, or $0.23 per share, in Q2 2025.
Cash, cash equivalents and short-term investments were $31.5 million as of June 30, 2026, down from $44.3 million at December 31, 2025; topline data from the Phase 2 studies are expected in September 2026.
Alpha and Omega Semiconductor (AOS) reported fiscal fourth-quarter revenue of $170.4 million, down 3.5% from a year earlier and up 4.0% from the March quarter, with a GAAP net loss of $13.1 million, or $0.43 per diluted share, compared with a $77.1 million loss a year earlier. It guided fiscal first-quarter revenue to $176 million, plus or minus $10 million. Revenue and non-GAAP profit declined year over year, while the quarter improved from the prior quarter.
Q4 revenue was $170.4 million, versus $176.5 million a year earlier and $163.8 million in the March 2026 quarter.
GAAP net loss was $13.1 million ($0.43 per diluted share), versus a $77.1 million loss ($2.58 per share) a year earlier; non-GAAP net loss was $0.13 per share, versus non-GAAP earnings of $0.02 per share a year earlier.
Fiscal 2026 revenue was $678.9 million, versus $696.2 million in fiscal 2025; GAAP net loss was $42.3 million, versus $97.0 million.
Guidance for the quarter ending September 30, 2026: revenue of $176 million plus or minus $10 million and non-GAAP gross margin of 24.5% plus or minus 1%.
SeaStar Medical reported second quarter 2026 results, with net revenue of about $0.6 million, up from about $0.3 million a year earlier, driven by growth in QUELIMMUNE sales. The net loss widened to about $3.7 million, or $0.91 per share, from about $2.0 million, or $1.77 per share, as research and development and general and administrative expenses rose, and cash fell to $7.0 million at June 30, 2026 from $12.0 million at December 31, 2025.
Net revenue for the quarter was about $0.6 million versus about $0.3 million in the second quarter of 2025; the company added 3 new QUELIMMUNE customers, bringing the total to 20.
Research and development expenses rose to $2.5 million from $1.0 million, and general and administrative expenses rose to about $1.8 million from $1.0 million.
Net loss was about $3.7 million, or $0.91 per share, on about 4.1 million weighted-average shares, compared with about $2.0 million, or $1.77 per share, on about 1.1 million shares a year earlier.
Cash was $7.0 million at June 30, 2026, down from $12.0 million at December 31, 2025.
Kura Oncology reported second quarter 2026 results, its second full quarter of KOMZIFTI sales. Total revenue rose to $20.9 million from $15.3 million a year earlier, but the net loss widened to $68.3 million, or $0.77 per share, from $66.1 million, or $0.75 per share. Cash, cash equivalents and short-term investments fell to $519.0 million at June 30, 2026, from $667.2 million at December 31, 2025, and the company cites $180 million in expected collaboration payments from Kyowa Kirin.
Net product revenue was $9.1 million, compared with none in 2Q 2025; new patient starts were about 115, up 35% from 1Q 2026.
Collaboration revenue fell to $11.8 million from $15.3 million in 2Q 2025.
Net loss was $68.3 million, or $0.77 per share, versus $66.1 million, or $0.75 per share, a year earlier.
Cash and short-term investments were $519.0 million at June 30, 2026, plus $180 million in anticipated Kyowa Kirin collaboration payments.
ITG reported second-quarter 2026 results, with revenue up 38% year over year to $404.6 million and Adjusted EBITDA up 21% to $52.2 million, but net income fell to $1.8 million from $11.6 million a year earlier. The company also issued its first full-year 2026 outlook, calling for revenue of $1,556 million and Adjusted EBITDA of $202 million, and said it completed its initial public offering in July with net proceeds mainly used to repay debt.
Revenue rose 38% year over year to $404.6 million; net income was $1.8 million versus $11.6 million in Q2 2025.
Adjusted EBITDA margin was 12.9%, down from 14.8% a year earlier, which management attributed to startup and public-company readiness costs.
FY 2026 outlook: revenue of $1,556 million (+35%) and Adjusted EBITDA of $202 million (+36%).
NTM backlog was $1,517 million as of June 30, 2026, compared with $1,259 million a year earlier.
Omeros reported second-quarter 2026 net product revenue of $28.5 million for YARTEMLEA, up from $9.9 million in the first quarter, and an operating gain of $0.1 million after a $17.4 million operating loss in the first quarter. GAAP net income fell to $13.2 million, or $0.18 per share, from $56.1 million in the first quarter, which included a larger $73.1 million non-cash gain. The company also completed July repurchases that cut its 2029 Notes principal to about $40.3 million and reduced potential conversion shares.
Net revenue of $28.5 million in Q2 2026 versus $9.9 million in Q1 2026; gross revenue was $32.2 million
Net income of $13.2 million ($0.18 per share) versus $56.1 million in Q1, with non-cash gains of $11.5 million in Q2 and $73.1 million in Q1
Non-GAAP adjusted net income of $1.8 million ($0.02 per share) in Q2 versus an adjusted net loss of $17.1 million in Q1
Cash and short-term investments of $132.0 million at June 30, 2026; 2029 Notes repurchases totaled $60.2 million in July 2026
Harmonic reported preliminary unaudited Q2 2026 results for the quarter ended July 3, 2026, with Broadband net revenue of $133.5 million, up from $86.9 million a year earlier, and GAAP continuing-operations net income per share of $0.16 versus a $(0.01) loss. The company raised its full-year 2026 Broadband revenue outlook to $505 million-$525 million, but total company GAAP results were a loss of $(0.02) per share after a $19.4 million loss from discontinued operations tied to the Video business sale.
Q2 2026 Broadband net revenue was $133.5 million, up 54% from $86.9 million in Q2 2025; Rest-of-Market revenue grew 44%
GAAP net income per share from continuing operations was $0.16 in Q2 2026; total company GAAP net loss per share was $(0.02) including discontinued operations
2026 GAAP revenue guidance raised to $505 million-$525 million; Q3 2026 GAAP revenue guidance is $125 million-$135 million
Video business sale to Leone Media Inc. (MediaKind) closed June 16, 2026 with $137.9 million in proceeds at closing; cash was $231.9 million at July 3, 2026
Cerebras reported second-quarter 2026 GAAP total revenue of $180.1 million, up 74% from a year earlier, and core revenue of $209.9 million, up 103%. The company posted a GAAP net loss of $450.5 million, compared with net income of $309.5 million a year earlier, which included a $363.3 million forward contract benefit. It raised its full-year 2026 core revenue outlook to $880 million to $890 million.
GAAP total revenue was $180.1 million, up 74% year over year; core total revenue was $209.9 million, up 103%.
GAAP net loss was $450.5 million, or $2.98 per share, versus net income of $309.5 million, or $1.91 diluted per share, in Q2 2025.
Full-year 2026 core revenue outlook raised to $880 million to $890 million; Q3 2026 core revenue expected at $214 million to $216 million.
Remaining performance obligations were $25.4 billion as of June 30, 2026.
Sera Prognostics reported second-quarter 2026 results on August 12, 2026, in a press release furnished as Exhibit 99.1. Revenue rose to $30,000 from $17,000, but operating expenses increased to $10.0 million and the net loss widened to $9.1 million from $8.0 million. The company said it ended the quarter with about $80.3 million in cash, cash equivalents and available-for-sale securities.
Q2 2026 revenue was $30,000, up from $17,000 in Q2 2025.
Net loss was $9.1 million, or $0.18 per share, versus $8.0 million, or $0.16 per share, a year earlier.
Total operating expenses were $10.0 million, compared with $9.3 million in the prior-year quarter.
Cash, cash equivalents and available-for-sale securities were about $80.3 million, which the company says will fund operations through 2029.
Talphera reported no revenue for the second quarter of 2026 and a net loss of $4.3 million, or $0.06 per share, versus a net loss of $3.5 million, or $0.10 per share, a year earlier. The dollar loss grew, but the per-share loss narrowed as weighted shares rose to 75.5 million from 34.5 million. The company said NEPHRO CRRT study enrollment reached 75%, with completion expected this year.
Net loss of $4.3 million, or $0.06 per share, for Q2 2026, compared with $3.5 million, or $0.10 per share, for Q2 2025
Combined R&D and SG&A expenses of $3.9 million, up from $3.7 million, mainly due to higher Niyad development expenses
Cash, cash equivalents and investments of $17.1 million at June 30, 2026, down from $20.4 million at December 31, 2025
NEPHRO CRRT study 75% enrolled; company regained Nasdaq compliance with the $1 bid price rule
Inovio reported a second-quarter 2026 net loss of $6.0 million, or $0.07 per share, down from $23.5 million, or $0.61 per share, a year earlier. The company said the decline was driven mainly by a $13.9 million non-cash gain on warrant liabilities, while operating expenses fell to $18.6 million from $23.1 million. Cash and short-term investments were $36.7 million at June 30, 2026, down from $58.5 million at December 31, 2025, before about $18.3 million in July offering proceeds.
Net loss of $6.0 million, or $0.07 per share, versus $23.5 million, or $0.61 per share, in Q2 2025
Non-cash warrant liability gain of $13.9 million; total operating expenses fell to $18.6 million from $23.1 million
Cash, cash equivalents and short-term investments of $36.7 million at June 30, 2026, excluding about $18.3 million in July offering proceeds
Cash expected to fund operations into late first quarter 2027, through a potential INO-3107 launch if approved; FDA PDUFA target date is October 30, 2026
Andersen Group reported second-quarter 2026 revenue of $217.7 million, up 23.7% from a year earlier, and reaffirmed its full-year 2026 guidance. The company still posted a net loss of $10.1 million for the quarter, though that was much smaller than the $96.0 million loss a year earlier, which it attributed mainly to non-cash equity-based compensation.
Q2 2026 revenue was $217.7 million, up 23.7% from $176.0 million; six-month revenue was $458.4 million, up 19.4%.
Q2 net loss was $10.1 million ($0.08 basic and $0.09 diluted per share), compared with a $96.0 million net loss in Q2 2025.
Adjusted net income rose 38.8% to $39.0 million in Q2; the company changed its non-GAAP definition to exclude all non-cash equity-based compensation.
Full-year 2026 guidance was reaffirmed: revenue of about $980 million to $1 billion and Adjusted EBITDA of about $225 million to $250 million.
QT Imaging reported second-quarter 2026 revenue of $7.4 million, up 103% from a year earlier, and reaffirmed its full-year 2026 revenue guidance of approximately $39 million. The net loss widened to $11.1 million, or $0.75 per share, mainly due to an $8.3 million non-cash loss on debt extinguishment tied to the modification of its Lynrock Lake term loan.
Q2 2026 revenue was $7.4 million, up from $3.7 million; the company shipped 15 scanners versus eight a year earlier.
Gross margin fell to 41% from 50%, which the company said was in line with its projections for U.S. sales.
Net loss was $11.1 million, or $0.75 per share, versus $4.0 million, or $0.42 per share, in Q2 2025.
Cash and restricted cash were $14.2 million as of August 7, 2026, after a $10.0 million public offering; the term loan maturity was extended from March 31, 2027 to March 31, 2029.
Spire Global reported second quarter 2026 revenue of $18.0 million, down 6% from a year earlier, mainly because it sold its maritime business in April 2025. Excluding maritime, revenue rose 16% year over year, and the company reported a net loss of $20.0 million compared with prior-year net income of $119.6 million, which included a $154.3 million gain on the business sale. The company reaffirmed its full-year 2026 revenue guidance of $75.0 million to $85.0 million.
Q2 2026 revenue was $18.0 million, down 6% year over year and up 14% sequentially; excluding maritime, revenue rose 16% year over year.
Net loss was $20.0 million, versus prior-year net income of $119.6 million that included a $154.3 million gain on sale of a business.
Adjusted EBITDA was a loss of $8.6 million, improved 16% from a loss of $10.2 million a year earlier.
Full-year 2026 revenue guidance of $75.0 million to $85.0 million was reaffirmed; cash, equivalents and marketable securities were $91.7 million as of June 30, 2026.
Nortech Systems reported second quarter 2026 net sales of $33.5 million, up from $30.7 million a year earlier, and net income of $316 thousand, or $0.11 per basic share, compared with $0.12 a year earlier. Adjusted EBITDA fell 12.6% to $938 thousand, while total backlog rose 20% to $93.8 million, which the company says signals future business prospects.
Q2 2026 net sales of $33.5 million vs. $30.7 million in Q2 2025, up 9.3%
Q2 2026 net income of $316 thousand, or $0.11 per basic share, vs. $313 thousand, or $0.12, in Q2 2025
Adjusted EBITDA of $938 thousand in Q2 2026 vs. $1.1 million in Q2 2025, down 12.6%
Total backlog of $93.8 million as of June 30, 2026, up 20% from June 30, 2025
On August 6, 2026, AmpliTech entered into Amendment No. 2 to its asset purchase agreement with Titan Crest, LLC and an affiliate. The company said Titan's substantial delinquency in delivering products delayed its development work, including documentation for 5G ORAN radio products. The amendment lowers the purchase price from $8 million to $7 million, and the remaining $2 million is payable only after the design package is transferred and the manufacturing partner confirms it is suitable for full production.
Amendment No. 2 dated August 6, 2026 amends the asset purchase agreement dated March 26, 2025, as amended April 15, 2025.
Aggregate purchase price reduced from $8,000,000 to $7,000,000.
Remaining $2,000,000 to be paid as $1,000,000 in cash and $1,000,000 in restricted common stock, priced on the 30-trading-day VWAP before the Transfer.
Titan was released from most remaining covenants and indemnities, which the affiliate assumed; the company did not waive pre-amendment claims against Titan or the affiliate.
Grocery Outlet reported second-quarter fiscal 2026 net sales up 1.1% to $1.19 billion and GAAP net income of $5.6 million, or $0.06 per diluted share, versus $5.0 million a year earlier. Adjusted net income fell to $20.3 million from $22.8 million, and the first half included a $158.0 million goodwill impairment that produced a net loss of $174.7 million. The company narrowed its fiscal 2026 guidance, raising the low end of its adjusted EBITDA and adjusted diluted EPS ranges.
Q2 net sales rose 1.1% to $1.19 billion, but comparable store sales fell 0.3% and gross margin declined to 30.2% from 30.6%.
First-half net loss of $174.7 million, or $(1.77) per diluted share, reflects a $158.0 million non-cash goodwill impairment recorded in Q1.
Fiscal 2026 guidance now calls for adjusted EBITDA of $225 million to $235 million (previously $220 million to $235 million) and diluted adjusted EPS of $0.51 to $0.55 (previously $0.45 to $0.55).
Spectral AI reported second-quarter 2026 results on August 11, 2026. Revenue fell to $3.5 million from $5.1 million, gross margin dropped to 31.6% from 45.2%, and the operating loss widened to $4.3 million from $2.1 million. The net loss narrowed to $4.2 million because of a $0.7 million warrant liability gain, and the company reiterated its 2026 revenue guidance of about $18.5 million.
Q2 2026 revenue was $3.5 million versus $5.1 million a year earlier, reflecting lower reimbursed costs under the BARDA contract.
Q2 2026 net loss was $4.2 million, or $0.13 per share, versus $8.0 million, or $0.31 per share, mainly due to a warrant liability fair value change.
Operating expenses rose to $5.4 million from $4.4 million, and gross margin fell to 31.6% from 45.2%.
Cash was $14.0 million at June 30, 2026, and the company reiterated 2026 revenue guidance of about $18.5 million.
Capstone Energy+ reported fiscal first quarter 2027 results, with revenue of $24.9 million, down from $27.9 million a year earlier, as large product order timing and lower rental utilization weighed on sales. Gross profit rose 16% to $8.8 million and the company reported net income of approximately $0.04 million, compared with a net loss of $0.7 million a year earlier, though the loss attributable to common stockholders after a $1.0 million preferred unit accretion adjustment was $0.03 per share.
Revenue was $24.9 million, compared with $27.9 million in Q1 2026; Parts and Service revenue rose 21% to $9.7 million.
Gross margin expanded 800 basis points to 35% from 27%, and income from operations was $1.0 million versus a $0.2 million loss a year earlier.
Net cash provided by operating activities was $5.4 million, including a $3.7 million customer deposit; cash and restricted cash totaled $32.3 million at June 30, 2026.
Adjusted EBITDA, a non-GAAP measure, was $2.7 million in both periods.
CVD Equipment reported second-quarter 2026 results that were driven by the April 1, 2026 sale of its SDC division for $17.4 million. Net income of $12.6 million included a $13.9 million gain on the divestiture, while revenue from continuing operations fell 42.6% to $2.0 million and the continuing-operations loss widened. Shareholders should note that a customer tied to a $0.8 million system order has filed a prepackaged Chapter 11 case, which the company is still evaluating.
Revenue from continuing operations was $2.0 million, down 42.6% from the prior-year quarter.
Net loss from continuing operations was $1.4 million, or $0.20 per share, versus $0.19 per share a year earlier.
Net income of $12.6 million included a $13.9 million gain on the SDC divestiture; cash rose to $23.5 million with no long-term debt.
A customer tied to a $0.8 million system order filed a prepackaged Chapter 11 case after quarter-end; backlog was $3.9 million at June 30, 2026.
New Concept Energy reported a second-quarter 2026 net loss from continuing operations of $66,000, up from a $18,000 loss a year earlier, even though revenue rose slightly to $41,000. Higher corporate general and administrative expenses of $129,000 outweighed the small revenue gain and lower interest income, so the company lost more money per share than in the prior-year quarter.
Q2 2026 net loss of $66,000, or $(0.01) per share, versus a net loss of $18,000, or $(0.00) per share, in Q2 2025
Q2 2026 revenue of $41,000, including $26,000 rental income and $15,000 management fees, versus $40,000 in Q2 2025
Corporate general and administrative expenses rose to $129,000 from $85,000; interest income fell to $35,000 from $42,000
Natural Gas Services Group reported record second-quarter 2026 rental revenue of $49.4 million and record adjusted EBITDA of $25.1 million, and raised its full-year 2026 adjusted EBITDA guidance. Reported net income fell year over year to $3.8 million, or $0.30 per diluted share, after about $3.3 million of Flatrock acquisition transaction costs.
Q2 2026 rental revenue was $49.4 million, up about 25% from the prior-year quarter; adjusted EBITDA was $25.1 million, up 27.4%.
Reported net income was $3.8 million, or $0.30 per diluted share, versus $5.2 million, or $0.41, a year earlier; excluding transaction costs, adjusted net income was $6.1 million, or $0.47 per diluted share.
Full-year 2026 adjusted EBITDA guidance was raised to $103 million-$108 million from $92.5 million-$97.5 million; growth capital expenditure guidance was raised to $60 million-$80 million from $55 million-$70 million.
Unicycive reported a second-quarter 2026 net loss of $1.7 million, or $(0.06) per share, versus $6.5 million, or $(0.52) per share, a year earlier, mainly because of an $8.0 million increase in the fair value of its warrant liability. Operating expenses rose to $10.1 million from $7.0 million, and the company disclosed a June 2026 FDA Complete Response Letter for its oxylanthanum carbonate NDA that cites the same third-party manufacturing deficiencies as a June 2025 letter.
Net loss was $1.7 million ($(0.06) per share) for the quarter ended June 30, 2026, down from $6.5 million ($(0.52) per share) a year earlier.
Change in fair value of warrant liability was a gain of $8.0 million, compared with $0.4 million in the prior-year quarter.
Operating expenses were $10.1 million, including G&A of $7.4 million and R&D of $2.8 million.
Cash, cash equivalents and marketable securities totaled $61.4 million as of June 30, 2026, with expected runway into 2027.
Milestone Pharmaceuticals reported second-quarter 2026 results with first product revenue of $559,000 for CARDAMYST, which launched in mid-February 2026. The net loss widened to $28.6 million, or $0.21 per share, from $13.0 million, or $0.20 per share, a year earlier, driven by higher selling, general and administrative expense tied to the launch. The company said its $170.6 million in cash and short-term investments is expected to fund operations into the second half of 2027.
Q2 2026 product revenue was $559,000, compared with none in Q2 2025; six-month product revenue was $797,000.
Q2 2026 net loss was $28.6 million, or $0.21 per share, versus $13.0 million, or $0.20 per share, in Q2 2025.
Selling, general and administrative expense rose to $22.6 million from $8.9 million, which the company attributed to CARDAMYST launch costs.
Cash, cash equivalents and short-term investments were $170.6 million at June 30, 2026, versus $106.0 million at December 31, 2025.
Applied Aerospace & Defense reported record second-quarter 2026 revenue of $167.3 million, up 47.4% from a year earlier, and record Adjusted EBITDA of $36.4 million. The company also reported a net loss of $154.0 million, mainly from share-based compensation and transaction expenses tied to its June 2026 initial public offering. The company gave full-year 2026 guidance of $670 million to $690 million in revenue and $150 million to $155 million in Adjusted EBITDA.
Q2 2026 revenue was $167.3 million, up from $113.5 million in Q2 2025; net loss was $154.0 million, or $1.04 per share, versus a net loss of $4.7 million, or $0.05 per share, a year earlier.
Share-based compensation expense was $110.1 million in the quarter, and transaction costs were $5.2 million.
Adjusted EBITDA was $36.4 million, up 38.5%, with an Adjusted EBITDA margin of 21.8% versus 23.2% a year earlier.
Full-year 2026 outlook: revenue of $670 million to $690 million and Adjusted EBITDA of $150 million to $155 million; backlog was $1.13 billion as of June 30, 2026.
Humacyte reported second quarter 2026 total revenue of $0.4 million, up from $0.3 million a year earlier, and a net loss of $36.8 million, compared with $37.7 million in the prior-year quarter. For the six months, the company swung to a net loss of $54.4 million from net income of $1.5 million, mainly due to a non-cash remeasurement of its contingent earnout liability, which matters for shareholders because it shows how non-operating accounting items can outweigh operating results.
Q2 2026 total revenue was $0.4 million versus $0.3 million in Q2 2025; contract revenue was zero after a prior-year research collaboration ended.
Q2 2026 net loss was $36.8 million ($0.16 per share) versus $37.7 million ($0.24 per share) a year earlier.
Six-month net loss was $54.4 million, compared with net income of $1.5 million in the first six months of 2025, driven by the non-cash remeasurement of the contingent earnout liability.
Cash, cash equivalents and restricted cash were $80.3 million at June 30, 2026, after a June 2026 public offering that raised gross proceeds of $57.5 million.
Octave Intelligence reported second quarter 2026 total revenue of $398 million, down 4% year over year, while annualized recurring revenue rose 7% to $1,143 million. A $2,135 million non-cash impairment charge drove a net loss of $1,971 million, or $7.34 per share, though adjusted EPS was flat at $0.36 and free cash flow was $93 million. The company says the charges did not affect cash flows or debt covenant compliance, and it gave initial full-year 2026 revenue guidance of $1,635 million to $1,665 million.
Q2 2026 total revenue was $398 million, down from $413 million a year earlier; recurring revenue rose 6% to $283 million.
Net loss was $1,971 million (EPS of -$7.34), including a $1,671 million goodwill impairment and a $464 million trademark impairment.
Adjusted EPS was $0.36, the same as Q2 2025; free cash flow was $93 million.
Initial guidance: Q3 2026 revenue of $400 million to $410 million and full-year 2026 revenue of $1,635 million to $1,665 million.
Trimble reported second-quarter 2026 revenue of $972.0 million, up 11 percent year over year, and raised its full-year 2026 revenue and earnings guidance. A $562.0 million goodwill impairment tied to the Transportation and Logistics segment drove a GAAP net loss of $471.7 million, while non-GAAP net income was $200.3 million. The board also approved a new $1.0 billion share repurchase authorization with no expiration date, replacing the prior authorization that had $608.2 million remaining.
Q2 2026 revenue was $972.0 million, up 11 percent; non-GAAP operating income was $260.6 million, or 26.8 percent of revenue.
GAAP diluted loss per share was $(2.02) for the quarter, including a $562.0 million goodwill impairment; non-GAAP diluted EPS was $0.86.
Full-year 2026 guidance: revenue of $3,900 million to $3,950 million and non-GAAP EPS of $3.60 to $3.70; GAAP loss per share of $0.07 to $0.12 is expected.
Board authorized up to $1.0 billion in share repurchases on August 10, 2026; the prior authorization was cancelled.
Sound Point Meridian Capital's investment adviser agreed to temporarily waive part of its base management and incentive fees from July 1 through December 31, 2026. The company also reported first fiscal quarter results with GAAP net income of $17.5 million, while its estimated net asset value per common share at July 31, 2026 was between $9.56 and $9.66, below the $9.88 reported at June 30, 2026.
Adviser waiver for July 1 to December 31, 2026: base management fee cut from 1.75% to 1.50%, and incentive fee share above the catch-up range cut from 20% to 15%; the adviser may not seek reimbursement of waived amounts.
Quarter ended June 30, 2026: net investment income of $5.1 million ($0.24 per share), realized loss of $12.8 million, unrealized gain of $25.2 million, and GAAP net income of $17.5 million ($0.83 per share).
Net asset value per common share was $9.88 at June 30, 2026, and management estimated a range of $9.56 to $9.66 at July 31, 2026.
Declared $0.13 per share monthly common distributions, payable October 30, November 30 and December 31, 2026, with record dates of October 15, November 13 and December 15, 2026.
BETA Technologies reported second quarter 2026 revenue of $14.7 million, up from $6.0 million a year earlier, while its net loss widened to $148.8 million from $80.4 million. The company raised its full-year 2026 revenue outlook to $42 million to $50 million and set its Adjusted EBITDA outlook at a loss of $400 million to $445 million, so shareholders see higher sales alongside larger losses.
Q2 2026 revenues were $14.7 million versus $6.0 million in Q2 2025.
Q2 2026 net loss was $148.8 million versus $80.4 million a year earlier; Adjusted EBITDA loss was $109.8 million.
Full-year 2026 revenue guidance raised to $42 million to $50 million; Adjusted EBITDA guidance set at a loss of $400 million to $445 million.
Cash and cash equivalents were $1,479.5 million as of June 30, 2026, compared with $174.5 million a year earlier.
American Strategic Investment Co. (NYSE: NYC) reported second-quarter 2026 results with revenue of $7.3 million, down from $12.2 million a year earlier, mainly due to the 2025 disposition of 1140 Avenue of the Americas. Its net loss narrowed to $8.3 million from $41.7 million, a period that included a $30.6 million impairment charge in 2025, and Adjusted EBITDA rose to $2.4 million from $0.4 million. Shareholders face lower rental revenue and a still-substantial net debt of $248.6 million, while the company said on July 22, 2026 that it had regained NYSE market capitalization and stockholders' equity compliance.
Revenue was $7.3 million versus $12.2 million in Q2 2025, primarily reflecting the 1140 Avenue of the Americas disposition
Net loss attributable to common stockholders was $8.3 million, or $3.04 per share, versus $41.7 million, or $16.39 per share, a year earlier
Cash NOI was $3.1 million versus $4.3 million; the company held $2.4 million of cash and cash equivalents at June 30, 2026
Net debt was $248.6 million, equal to 59.6% of gross asset value; on July 22, 2026 the NYSE said the company was back in compliance with its listing requirements
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.